glp-1 drug delivery devices FDA Actions on Compounded Drugs Reshape Market-Xinfuda Vaxess raises funds for GLP-1
Description
Interestingly, higher incidence of diabetic retinopathy (DR) complications was noted in patients taking semaglutide (3.0%) compared to placebo (1.5%) in clinical trials, with greater risk in those with a history of DR [32]
doi: 10.1370/afm
[DOI] [PMC free article] [PubMed] [Google Scholar] 119
GLP-1 has different forms include GLP-1(1-37), GLP-1(7-36)amide and GLP-1(7-37) (89)
It shares the same receptor targets as survodutide but has a different molecular structure and pharmacokinetic profile
10-year incidence of diabetes and associated risk factors in Greece: the ATTICA study (2002-2012) Rev Diabet Stud
